Solventum Corp (SOLV)
UndervaluedFundamental
72
Price
$85.41
Market Cap
$14.75B
Part 1 · What the company is worth
Overview
Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies for original equipment manufacturers. The Dental Solutions segment provides dental and orthodontic products, including brackets, aligners, restorative cements, and bonding agents to span the life of the tooth, and products for preventative dental care, direct and indirect restoration, and orthodontic needs. The Health Information Systems segment offers healthcare systems with software solutions comprising computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms. The company sells its products and services through direct-to-consumer, distribution, key account management, inside sales, and e-commerce. Solventum Corporation was incorporated in 2023 and is headquartered in Eagan, Minnesota.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance Sheet & Liquidity
Revenue
$8.31B
Trailing 12 months (through 6/30/2026)
Net Income
$1.43B
Trailing 12 months (through 6/30/2026)
Free Cash Flow
$-10M
Total Equity
$5.05B
Total Liabilities
$9.24B
Current Ratio
1.02
Interest Coverage
-
Debt/EBITDA
1.98
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$124.79
Current Price
$85.41
Margin of Safety
+31.6%
Fair Value Range
$81.11 - $168.46
Spread across the valuation methods used, not a statistically calibrated confidence interval.
Estimation Methods
Valuation Metrics
P/E Ratio
10.43
ROE
30.8%
P/B Ratio
3.03
P/FCF
-
Gross Margin
54.7%
ROIC
15.5%
Profitability Radar
Value Creation (Economic Moat)
ROIC
15.5%
WACC
6.3%
ROIC − WACC
+9.2 pp
ROIC exceeds the cost of capital — the company is creating value for shareholders.
Fundamental Analysis Criteria
Passed (15)
- EPS shows upward trend
- Price CAGR 14.94%
- ROIC 15.5%
- Gross margin 54.7%
- Debt/equity ratio
- Operating margin 25.0%
- Current ratio
- Debt/EBITDA
- Return on tangible assets
- DCF valuation (Undervalued)
- ROE 29.0%
- Earnings surprise, average 11.0%
- Share dilution 1.0%
- Net margin trend 17.3% vs 4.5%
- Piotroski F-Score 7/9
Failed (6)
- EPS CAGR 4.51%
- P/B ratio 3.03
- Positive free cash flow
- Low reliance on intangibles
- Price below Graham Number
- Earnings quality (operating cash flow / net income) 0.15
Unavailable (6)
- P/FCF –
- Dividend payout –
- CapEx intensity
- Interest coverage
- Revenue growth 5Y
- PEG ratio (needs P/E > 0 and growth > 0)
Piotroski F-Score
Strong financial health
Earnings Quality
Low quality: investigate accounting
Share Dilution
Share count is stable
Institutional Holdings
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Mr. Bryan C. Hanson | CEO & Director | 58 |
| Mr. Wayde D. McMillan | Executive VP & CFO | 55 |
| Ms. Amy Landucci | Chief Information & Digital Officer | 50 |
| Ms. Marcela A. Kirberger | Chief Corporate & Legal Affairs Officer & Corporate Secretary | 58 |
| Ms. Heather L. Knight | Chief Commercial Officer | 53 |
| Mr. Neil C. Zieselman | Senior VP, Controller & Chief Accounting Officer | 49 |
| Ms. Amy Wakeham | Senior Vice President of Investor Relations & External Finance Communications | - |
| Ms. Rachel H. Ellingson | Chief Strategy & Corporate Development Officer | 55 |
| Ms. Tammy L. Gomez | Chief Human Resources Officer | 52 |
| Mr. Paul S. Harrington | Chief Supply Chain Officer | 55 |
Audit Risk
10
Board Risk
3
Compensation Risk
8
Shareholder Rights Risk
6
Documents
- View document
Annual Report (10-K)
A yearly overview of the business, its financial results, and the risks it faces.
Filed on 2026-02-27
- View document
Quarterly Report (10-Q)
A snapshot of financial performance for the most recent three-month period.
Filed on 2026-08-05
- View document
Current Report (8-K)
An announcement of a major event, such as a leadership change or big news.
Filed on 2026-08-05
via SEC EDGAR
Income History
via SEC EDGAR
Part 2 · The price and its context
This part shows how the price has behaved, not whether the company is worth owning. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Market Reaction Profile
How much SOLV moves, measured on its daily prices.
More volatile than 29% of the tracked stocks (90-day volatility).
- Volatility 30d
- 19.7%
- Volatility 90d
- 28.2%
- Beta vs S&P 500 (1y)
- 0.55Correlation 0.24
- Max drawdown (12m)
- -27.5%
- ATR (14d, % of price)
- 2.40%
Earnings reactions
How SOLV moved around its past quarterly results.
Next earnings release
Nov 5, 2026 · In 12 days · Time not known
EPS estimate: 1.34Revenue estimate: $1.9B
What usually happens
- Over the last 10 releases the stock moved a median of 3.5% the next day, up or down.
- Next-day moves: up 5, down 5 (out of 10).
- Of the 4 releases that beat estimates, the stock fell the next day after 2.
Release history
| Date | When | EPS est. | EPS actual | Surprise | Gap | 1 day | 5 days |
|---|---|---|---|---|---|---|---|
| Aug 5, 2026 | After the close | 1.94 | 2.55 | +31.2% | +2.3% | -5.2% | -2.5% |
| May 5, 2026 | After the close | 1.38 | 1.48 | +7.3% | -1.5% | +2.8% | +8.8% |
| Feb 26, 2026 | After the close | 1.53 | 1.57 | +2.9% | -5.1% | -3.6% | -8.0% |
| Nov 6, 2025 | After the close | 1.46 | 1.50 | +2.7% | +3.5% | +7.9% | +13.5% |
| Aug 7, 2025 | After the close | n/a | n/a | n/a | +3.4% | +2.0% | +1.7% |
| May 8, 2025 | After the close | n/a | n/a | n/a | +2.0% | +5.4% | +9.5% |
| Feb 27, 2025 | After the close | n/a | n/a | n/a | -3.0% | -4.4% | -9.2% |
| Nov 7, 2024 | After the close | n/a | n/a | n/a | +2.0% | -3.5% | -9.6% |
| Aug 8, 2024 | After the close | n/a | n/a | n/a | +2.3% | +3.3% | +0.3% |
| May 9, 2024 | Before the open | n/a | n/a | n/a | -1.4% | -2.4% | -6.0% |
Release dates from SEC 8-K filings.
Updated 10/24/2026
Historical statistics for educational purposes only. They are not forecasts and not investment advice.
Price reaction to the news
Latest news on SOLV and what the price did next.
Return of the stock minus return of SPY over the same days. A news item close to a price move did not necessarily cause it. Historical data for educational purposes only, not investment advice.
Latest News
Recent headlines for SOLV.
- 2/26/2026NEUTRALSolventum (SOLV) Q4 2025 Earnings Call Transcript
The transcript for Solventum Corporation's (SOLV) fourth-quarter 2025 earnings call has been made available, marking a routine event in the company's financial calendar. Solventum, a healthcare technology spin-off from 3M, is under investor scrutiny for its performance post-separation. While the release of the transcript is a standard step for transparency, the absence of the actual earnings content prevents an in-depth analysis. Investors are awaiting the detailed financial figures and future outlook to assess the business trajectory and potential implications for share value. Currently, the mere availability of the transcript, without the underlying data, provides no clear directional guidance for the market.